Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.
Haydar Frangoul, Josu de la Fuente, Yogi Chopra et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 clinical trial evaluated exa-cel, a cell therapy, in children aged 5 to 11 with transfusion-dependent β-thalassemia or sickle cell disease. The study found that 8 out of 8 children with β-thalassemia achieved transfusion independence, and 8 out of 8 children with sickle cell disease were free from severe vaso-occlusive crises after at least 16 months of follow-up.
Key findings
- 8 out of 8 children with transfusion-dependent β-thalassemia achieved transfusion independence.
- 8 out of 8 children with sickle cell disease were free from severe vaso-occlusive crises.
- All participants experienced at least one grade 3 or 4 adverse event.
- 2 children developed severe veno-occlusive liver disease related to busulfan conditioning.
Why it matters
The findings suggest that exa-cel may provide significant clinical benefits for children with transfusion-dependent β-thalassemia and sickle cell disease, potentially reducing the burden of these conditions. However, the occurrence of serious adverse events highlights the need for careful patient selection and monitoring.